×
For best experience we recommend to activate Javascript in your browser.
IRAK1 antibody (AA 212-434)
The Rabbit Polyclonal anti-IRAK1 antibody has been validated for WB, ELISA and IHC. It is suitable to detect IRAK1 in samples from Human.
Quick Overview for IRAK1 antibody (AA 212-434) (ABIN7569924)
Target
See all IRAK1 Antibodies
IRAK1
(Interleukin-1 Receptor-Associated Kinase 1 (IRAK1))
Reactivity
All reactivities for IRAK1 antibodies
Human
Host
All hosts for IRAK1 antibodies
Rabbit
Clonality
All clonalities for IRAK1 antibodies
Polyclonal
Conjugate
All conjugates for IRAK1 antibodies
This IRAK1 antibody is un-conjugated
Application
All applications for IRAK1 antibodies
Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
Product Details anti-IRAK1 Antibody
(hide)
Binding Specificity
All epitopes for IRAK1 antibodies
AA 212-434
Purpose
Anti-Human IRAK1 Polyclonal Antibody
Purification
Antigen affinity purification.
Immunogen
E. coli - derived recombinant Human IRAK1 (Phe212-Leu434).
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
0.01M PBS, pH 7.4, 50 % glycerol, 0.05 % Proclin 300.
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt.
Target Details for IRAK1
(hide)
Target
IRAK1
(Interleukin-1 Receptor-Associated Kinase 1 (IRAK1))
Alternative Name
IRAK1
Background
Interleukin-1 receptor-associated kinase 1, IRAK1, IRAK, IRAK-1
UniProt
P51617
Pathways
NF-kappaB Signaling , TLR Signaling , Neurotrophin Signaling Pathway , Activation of Innate immune Response , Cellular Response to Molecule of Bacterial Origin , Toll-Like Receptors Cascades
Recently viewed
(hide)
Chat with us , powered by LiveChat